BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.61B |
| Revenue (ttm) | 2.88B |
| Net Income (ttm) | -344.80M |
| Shares Out | n/a |
| EPS (ttm) | -1.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,540 |
| Average Volume | 1,526 |
| Open | 90.10 |
| Previous Close | 91.85 |
| Day's Range | 89.00 - 91.35 |
| 52-Week Range | 71.00 - 124.60 |
| Beta | 1.24 |
| RSI | 37.35 |
| Earnings Date | Aug 4, 2025 |
About BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]
Financial Performance
Financial StatementsNews
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr . Sho...
Pfizer/BioNTech updated COVID vaccine authorized in Canada
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquir...
CureVac's 2025 Mid-Year Financial Surge & Key Business Insights
BioNTech's acquisition of CureVac marks a pivotal moment in mRNA innovation, uniting strengths to push the boundaries of global healthcare. Jetzt den vollständigen Artikel lesen
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
CureVac Resolves Patent Dispute with Pfizer/BioNTech!
CureVac and GSK have settled patent disputes with BioNTech and Pfizer, securing $740 million and future royalties, while paving the way for global mRNA vaccine collaboration. Jetzt den vollständigen A...
EQS-News: CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
Issuer: CureVac / Key word(s): Patent CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech 08.08.2025 / 02:15 CET/CEST The issuer is solely responsible for the content of this announ...
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
BioNTech SE (NASDAQ: BNTX) reported a narrower loss for the second quarter on Monday . The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of 3.36 euros ...
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
BioNTech SE BNTX reported a narrower loss for the second quarter on Monday.
BioNTech SE 2025 Q2 - Results - Earnings Call Presentation
BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member...
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech SE BNTX reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech SE (NASDAQ: BNTX) reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 ...
BioNTech posts Q2 beat as revenue more than doubles
BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.
The drug maker reported a narrower-than-expected loss in the second quarter.
BioNTech's Q2 revenues double on higher COVID vaccine sales
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with P...
BioNTech GAAP EPS of -€1.60, revenue of €260.8M
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antib...
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE: KOS) is likely to report quarterly loss at $0.07 per share on revenue of $415.09 million. • Sohu.com (NASDAQ: SOHU) is likely to report ear...
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
BioNTech Q2 2025 Earnings Preview
A Look Ahead: BioNTech's Earnings Forecast
BioNTech (NASDAQ: BNTX) is set to give its latest quarterly earnings report on Monday, 2025-08-04. Here's what investors need to know before the announcement. Analysts estimate that BioNTech will rep...